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Abstract
This concise review summarises tissue and serum markers useful for differential diagnosis of germ cell tumours 
(GCT), with focus on the most common testicular GCT (TGCT). GCT are characterised by phenotypic hetero-
geneity due to largely retained embryonic pluripotency and aberrant somatic differentiation. TGCT that occur 
in young men are divided into two main types, seminoma and nonseminoma, both derived from a pre-invasive 
germ cell neoplasia in situ (GCNIS), which originates from transformed foetal gonocytes. In severely dysgenetic 
gonads, a GCNIS-resembling lesion is called gonadoblastoma. GCT occur rarely in young children (infantile 
GCT) in whom the pathogenesis is different (no GCNIS/gonadoblastoma stage) but the histopathological fea-
tures are similar to the adult GCT. The rare spermatocytic tumour of older men is derived from post-pubertal 
spermatogonia that clonally expand due to gain-of function mutations in survival-promoting genes (e.g. FGFR3, 
HRAS), thus this tumour has a different expression profile than GCNIS-derived TGCT. 
Clinically most informative immunohistochemical markers for GCT, except teratoma, are genes expressed in 
primordial germ cells/gonocytes and embryonic pluripotency-related factors, such as placental-like alkaline 
phosphatase (PLAP), OCT4 (POU5F1), NANOG, AP-2γ (TFAP2C) and LIN28, which are not expressed in 
normal adult germ cells. Some of these markers can also be used for immunocytochemistry to detect GCNIS or 
incipient tumours in semen samples. 
Gene expression in GCT is regulated in part by DNA and histone modifications, and the epigenetic profile of 
these tumours is characterised by genome-wide demethylation, except nonseminomas. In addition, a recently 
discovered mechanism of post-genomic gene expression regulation involves small non-coding RNAs, predomi-
nantly micro-RNA (miR). Testicular GCT display micro-RNA profiles similar to embryonic stem cells. Targeted 
miRNA-based blood tests for miR-371-3 and miR-367 clusters are currently under development and hold a great 
promise for the future. In some patients miR-based tests may be even more sensitive than the classical serum 
tumour markers, b-chorio-gonadotrophin (b-hCG), a-fetoprotein (AFP) and lactate dehydrogenase (LDH), 
which are currently used in the clinic.
In summary, research advances have provided clinicians with a panel of molecular markers, which allow spe-
cific diagnosis of various subtypes of GCT and are very useful for early detection at the precursor stage and for 
monitoring of patients during the follow-up. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 3, 177–188)
Key words: testis; germ cell neoplasia; testicular cancer; seminoma; embryonal carcinoma; carcinoma in situ; 
testis; spermatocytic tumour; tumour marker; PLAP; AP-2γ; micro-RNA; immunohistochemistry
Abbreviations: AFP — a-fetoprotein, CIS — carcino-
ma in situ testis (currently GCNIS), DSD — disorders 
of sex development, EC — embryonal carcinoma, 
GCNIS — germ cell neoplasia in situ (previously CIS), 
GCT — germ cell tumour, b-hCG — b-chorio-go -
nadotrophin, LDH — lactate dehydrogenase, PGC 
— primordial germ cell, TDS — testicular dysgenesis 
syndrome, TGCT — testicular germ cell tumour
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Introduction
Germ cell tumours (GCT) are a group of neoplasms 
with some unusual features in comparison to solid 
cancers that are derived from somatic cells. A striking 
feature of GCT is their phenotypic heterogeneity, due 
to retained embryonic pluripotency and subsequent 
aberrant somatic differentiation in a subset of these 
tumours, known as teratomas. This morphological 
heterogeneity has been causing difficulties in classi-
fication and histopathological diagnosis. During the 
recent decades, thanks to new tools of molecular bio-
logy, GCT have been characterised in greater detail 
and a number of novel diagnostic markers have been 
developed. In this article, we summarise research de-
velopments concerning histogenesis of different types 
of GCT and review immunohistochemical and serum 
markers which are clinically useful for differential 
diagnosis of GCT and their precursors.
Germ cell tumours can occur in any age, both in 
men and women. The tumours arise most often in the 
gonads but can be found in extragonadal locations, 
usually close to the midline of the body [1]. Malignant 
GCT are much more frequent in males, which can be 
explained by differences in biology of male and female 
germ cells, especially during development [2, 3]. In 
males, germ cell-derived malignancies occur predom-
inantly in the testis, thus testicular GCT (TGCT) are 
the focus of this review.
Histopathology and pathogenesis  
of germ cell neoplasms
Germ cell tumours in males occur in three age groups, 
and in each age group the tumours are derived from 
a different stage of germ cell development, as illus-
trated in Figure 1. 
The most common by far are TGCT that affect 
post-pubertal adolescents and young adults. Tes-
ticular tumours in this age group are derived from 
a pre-invasive stage, germ cell neoplasia in situ 
(GCNIS); a new term proposed by the most recent 
edition of World Health Organisation Classification 
of Tumours of the Male Genital Organs, which will 
be published in 2016. Previously used names were 
testicular carcinoma in situ (CIS) [4], intratubular 
germ cell neoplasia, unclassified (IGCNU) and tes-
ticular intraepithelial neoplasia (TIN). In severely 
dysgenetic gonads of individuals with disorders of sex 
development (DSD), the precursor lesion most often 
seen is gonadoblastoma. Depending on the degree 
of masculinisation of the gonad, either GCNIS or 
gonadoblastoma, or a mixture of both, may be present. 
GCNIS is enclosed in better masculinised tubules, 
while gonadoblastoma resides in nests of granulo-
sa-resembling cells, but the neoplastic germ cells 
have essentially the same phenotypic features [5–7]. 
A good marker for more masculinised Sertoli cells 
is SOX9, whereas granulosa-like cells surrounding 
gonadoblastoma cells express FOXL2 [8].
It is important for the understanding of the 
pathogenesis of GCNIS-derived TGCT that even 
though most of the patients are normally virilised 
males, these neoplasms are associated with disturbed 
early development of the testis, often manifested in 
adulthood as clusters of poorly formed tubules, un-
differentiated Sertoli cells, microlithiasis and Leydig 
cells micronodules [9]. Among the risk factors for 
GCNIS/TGCT, cryptorchidism, genital malforma-
tions, low percentage sex chromosome aneuploidy and 
some forms of infertility, are also linked to disturbed 
foetal development, hence all these conditions have 
been grouped within testicular dysgenesis syndrome 
(TDS) [10]. The incidence of TGCT and some other 
TDS disorders have been increasing around the word, 
suggesting a strong environmental component in the 
pathogenesis, but combined with genetic susceptibility 
[10–12]. Discussion on the aetiology of TGCT and 
TDS exceeds the scope of this review, so the readers 
are referred to recent comprehensive review articles 
on this topic [11, 13, 14]. 
TGCT of young adults are divided into two histo-
logical entities: seminoma and nonseminoma, but 
a combination of the above subtypes in one patient is 
quite common [15]. Seminoma is the most frequent 
type of these tumours (approximately 60% of cases) 
and consists of malignant germ cells that retain a germ 
cell phenotype similar to GCNIS/gonadoblastoma 
cells. Nonseminomas display a very heterogeneous 
histology and are usually composed of mixtures of 
embryonal carcinoma, mature or immature teratoma, 
choriocarcinoma and yolk sac tumour (also known 
as endodermal sinus tumour), although in rare cases 
these components may occur in a pure form [15]. 
Embryonal carcinoma is considered a repro-
grammed and transformed equivalent of embryonic 
stem cells and is characterised by pluripotency, which 
explains the presence of somatic cells within teratoma-
tous components, which are at differentiation stages 
that mimic embryonic development [16]. Although 
this review focusses on male GCT, it is important to 
mention that essentially the same histological entities 
are recognised in females where they occur mainly in 
the ovary but may also arise in extragonadal locations. 
The ovarian and extragonadal counterparts of semi-
noma are dysgerminoma (may be accompanied by 
gonadoblastoma in females with some Y-chromosome 
material in their genome) and germinoma, respective-
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ly, while the equivalent of nonseminoma in a female 
is nondysgerminoma, or simply malignant teratoma, 
if no other component is present [3]. 
Regardless of the gender, location and patho-
genesis, all the above mentioned GCT have similar 
molecular features. The GCT genome is character-
ised by polyploidisation and the presence of genomic 
gain of the short arm of chromosome 12p, often in 
the form of an isochromosome, i(12p) and a relative 
excess of the X chromosome (reviewed in [1, 3, 17]. 
The presence of i(12p) is considered pathognomonic 
for the germ cell origin of a tumour and is useful in 
differential diagnosis [18, 19].
TGCT in other age groups are rare. Childhood 
TGCT occur typically in infants and toddlers up to 
5 years of age, and histology at this age is either mature 
teratoma or yolk sac tumour [1, 20, 21]. Importantly, 
there is no GCNIS- or gonadoblastoma-like precursor 
lesion, suggesting that these tumours originate di-
rectly from PGC; however, the pathogenesis remains 
unknown [22, 23]. These tumours, mainly mature 
teratomas, may also occasionally be found in adult 
men beyond childhood, and can be distinguished from 
malignant TGCT of young adults by the absence of 
GCNIS and lack of gain of 12p [24, 25]. 
The third type of TGCT, which occurs in older 
men, with mean age of diagnosis around 50–55 years 
of age is spermatocytic tumour, previously known 
as spermatocytic seminoma [1, 26–28]. This tumour 
arises exclusively in the testis (no ovarian counterpart) 
and is not associated with GCNIS [29]. Spermatocytic 
tumour originates from post-pubertal spermatogonia 
which expand clonally due to gain-of-function mu-
tations in genes involved in pathways that increase 
spermatogonial survival/proliferation, e.g. FGFR3 and 
HRAS [30]. Spermatocytic tumour is characterised 
Figure 1. Schematic histogenesis of testicular germ cell tumours (TGCT) in relation to the normal development of germ 
cells. Normal germ cell development is shown in the green-shaded middle part of the Figure. Rare TGCT that are unrela-
ted to germ cell neoplasia in situ (GCNIS); infantile TGCT and spermatocytic tumour are shown in the upper part of the 
graph. The most common TGCT that are derived from foetal germ cells (gonocytes) via the stage of GCNIS are shown in 
the lower part of the Figure within the red ellipse. Abbreviations: CHC — choriocarcinoma; EC — embryonal carcinoma; 
ICM — inner cell mass; PGC — primordial germ cell; TER — teratoma; YST — yolk sac tumour
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by frequent amplification of a locus on the p arm of 
chromosome 9, with DMRT1 as a candidate gene [27].
Immunohistochemical markers useful  
for GCT diagnosis in tissue specimens
The first histochemical marker for GCNIS and 
GCNIS-derived TGCT was placental-like alkaline 
phosphatase (PLAP), previously widely used in animal 
models to detect PGCs [31]. The long postulated by 
our group similarity of GCNIS cells to foetal gono-
cytes [32] was first supported by immunohistochemical 
studies which looked at one or few proteins at the time 
[33–36]. Subsequently, a genome-wide microarray 
study corroborated this hypothesis by a direct com-
parison of GCNIS and gonocyte transcriptomes [37].
Likewise, pluripotent characteristics of GCT ob-
served previously by pathologists, has been demon-
strated by molecular studies, including numerous 
microarray studies, which detected in these tumours 
(excluding teratoma) as well as in human PGCs/gono-
cytes, a high expression of embryonic factors involved 
in pluripotency regulation, such as POU5F1(OCT4), 
NANOG, SOX2, REX1, UTF1 or LIN28 [38–47]. 
These studies have also identified differences between 
the GCT subtypes, e.g. seminoma/(dys)germinoma 
versus embryonal carcinoma or yolk sac tumour. It is 
not possible to list here all studies and all implicated 
genes, so the interested reader should consult recent 
systematic review articles [3, 48]. 
The above-mentioned studies provided a range 
of markers that have been validated for the identifi-
cation of GCNIS and seminoma/(dys)germinoma in 
tissue specimens by immunohistochemistry, including 
OCT4 [36, 39, 49, 50], NANOG [51, 52], LIN28 [47, 
53], AP-2γ [54–56], podoplanin (PDPN, M2A, D2-40, 
Aggrus) [57, 58], and KIT [33]. The markers that are 
useful in clinical practice and research are listed in 
Table 1. Immunohistochemistry is very helpful for 
the detection of GCNIS in testicular biopsies [59–61] 
and we suggest using at least two different markers 
for each tissue specimen, e.g. PLAP and OCT4 or 
PDPN (Figure 2).
For differential diagnosis of nonseminomas, a panel 
of several markers has to be used in order to identify 
the presence of different histological components, 
as shown in Table 1. For the detection of embryonal 
carcinoma, pluripotency markers OCT4 and NANOG 
are useful, but additional discriminative markers are 
needed to distinguish it from seminoma. We suggest 
to use SOX2 [43, 44, 62, 63] (Figure 3) or CD30 (both 
are positive in embryonal carcinoma but negative 
in seminoma), simultaneously with KIT or PDPN 
(positive in seminoma but negative in embryonal 
carcinoma) [64, 65]. Differentiated somatic elements 
within teratomas have expression profiles of various 
tissue lineages and no longer express pluripotency 
factors or germ cell-specific genes. 
Extraembryonic components yolk sac tumour 
and choriocarcinoma are usually admixed with other 
nonseminomatous elements, but may occur as pure 
tumours, especially in children. Regardless of the age 
and gender of the patient, these components have es-
sentially the same morphology and expression profiles 
[3, 21, 43, 48, 65]. Yolk sac tumour produces and secrets 
a-fetoprotein (AFP), which is detectable in serum and 
tumour tissue [66]. Among other immunohistochemical 
markers for yolk sac tumour the most informative are 
Glypican-3 (GPC3) and SALL4 [65, 67, 68] (Figure 3). 
Choriocarcinoma contains trophoblastic-like syncytia 
and secrets b-chorio-gonadotrophin (b-hCG) which 
is measurable in serum and detectable in tissues [66]. 
Other immunohistochemical markers, such as GPC3 
or SALL4 are present but are not specific for chorio-
carcinoma [69].
As far as spermatocytic tumour of older men is 
concerned, its gene expression profile — both at 
the transcript and protein level — resembles closely 
profiles of spermatogonia and early primary sper-
matocytes of the adult testis [26, 27, 70]. Accordingly, 
spermatocytic tumours do not express embryonic 
pluripotency genes and PGC/gonocyte specific 
markers, and markers of haploid spermatids (e.g. 
p19-INK4) are also negative [26]. Among the best 
markers for spermatocytic tumour are the so-called 
cancer-testis antigens: SSX1-4, MAGE-A4, MAGE3, 
NY-ESO-1/CTAG1A, GAGE4, SAGE1 [27, 70–74] 
(Figure 3). Other immunohistochemical markers in-
clude SYCP1, NSE (neuron-specific enolase), CHK2, 
VASA, UTF1, FGFR3 or HRAS, and DMRT1 [26, 
27, 30, 46, 71]. Recently, OCT2 was detected in 
a small subset of spermatocytic tumours and in A-dark 
spermatogonia [70], and in both cell types, OCT2 was 
found mutually exclusive with DMRT1 [75]. For diag-
nostic purposes in the clinics we suggest MAGE-A4 
(Figure 3) and DMRT1, which are the most robust 
immunohistochemical markers, as shown in Table 1.
Detection of GCNIS in semen samples by 
immunocytochemistry and histochemistry
Like other precancerous in situ changes, GCNIS can 
be detected before the invasive tumour has developed. 
This happens only rarely, mainly in patients who 
undergo testicular biopsies because of an increased 
risk of TGCT, such as DSD, contralateral testicular 
cancer, history of cryptorchidism or infertility, in 
particular if the testes are small and microlithasis is 
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Figure 2. Germ cell neoplasia in situ (GCNIS): histology and selected immunohistochemical markers. The two top 
microphotographs are haematoxylin-eosin (HE)-stained (left) and OCT4-stained (right), serial sections of an adult testis 
specimen with GCNIS (visible on the left of both images) and tubules with normal spermatogenesis (on the right); scale 
bar = 250 µm. The staining for OCT4 clearly helps to detect GCNIS. Sections stained with four commonly used immu-
nohistochemical markers (PLAP, OCT4, TFAP2C and D2-40) are shown at higher magnification below; scale bar = 50 µm. 
Tubules with GCNIS are shown side-by-side to tubules with ongoing spermatogenesis. Note an insert in the micrograph with 
TFAP2C (also known as AP-2γ), showing a GCNIS cell in a semen smear positive for TFAP2C (red colour, in the nucleus) 
and displaying a strong enzymatic reaction of alkaline phosphatase (blue colour, in the cytoplasm); scale bar = 10 µm
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Figure 3. Examples of immunohistochemical markers for different histological subtypes of testicular germ cell tumours. 
From the top: D2-40 in a seminoma (SEM), there are also two tubules with germ cell neoplasia in situ (GCNIS) visible; 
MAGE-A4 in a spermatocytic tumour (SPT), SOX2 and OCT4 in embryonal carcinoma (EC) containing differentiated 
teratomatous tissues (TER), the latter component negative for both markers, SALL4 and AFP in two different specimens 
of yolk sac tumours (YST). Scale bar = 100 µm
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visible on ultrasound examination [59, 60, 76, 77]. 
Giwercman was the first to demonstrate that GCNIS 
cells are occasionally exfoliated into semen and can 
be identified in the ejaculate by immunostaining 
for M2A/PDPN antigen [78]. However, cell surface 
markers were not optimal for this purpose, so more 
recently, we and others have exploited nuclear 
proteins, AP-2g or OCT4, which ought to be better 
protected from degradation in semen [79, 80]. The 
test was promising but had rather low sensitivity and 
required good experience to distinguish cells which 
were truly positive from occasionally false positive 
cells [79]. In another study from France, cancer-testis 
antigens, MAGE-A4 and NY-ESO-1 have been tested 
for suitability for detecting GCNIS cells in semen [81]. 
However, a serious drawback of this approach is that 
both antigens are also expressed in normal germ cells 
(spermatogonia and early primary spermatocytes), 
thus leading to false-positive results in healthy sub-
jects. Subsequently, our group has improved sensitiv-
ity of the AP-2g-based test by combining it with rapid 
histochemical staining detecting enzymatic activity of 
PLAP [82]. The double-staining method was further 
optimised by automated staining, slide scanning and 
imaging software, which increased the speed and ob-
jectivity of the test [83]. An example of GCNIS cells 
detected by this method is shown as an insert in Figure 
1. This approach is reliable in experienced hands, 
but the sensitivity of the assay remains low, because 
GCNIS cells in many patients do not readily exfoliate 
into semen. It follows that a negative result does not 
completely exclude the presence of a neoplasm in 
a testicle. However, the test is much less invasive that 
a surgical biopsy and can be performed repeatedly, 
so it may be considered to monitor for GCNIS also 
those patients who do not have a stringent indication 
for testicular biopsy.
Immunohistochemical markers  
of epigenetic modifications in TGCT 
In addition to the embryonic gene expression pat-
tern, epigenetic profiles of neoplastic germ cells 
resemble those of primordial germ cells (PGCs) 
and foetal gonocytes to a large extent [84, 85]. DNA 
methylation and histone modifications in GCNIS 
and TGCT are different from somatic cells, but also 
strikingly variable. Consistent DNA demethylation 
throughout the genome is observed in GCNIS and 
seminoma, whereas the genome of non-seminomas 
is methylated in a non-random manner with imprint-
ed genes left hypo-methylated [85–88]. This can be 
easily demonstrated in tissue specimens by immuno-
histochemical staining for 5-methyl-cytosine [84, 87]. 
The hypomethylation of GCNIS is apparently actively 
maintained by expression of APOBEC1 and base exci-
sion repair proteins MBD4, APEX1 and PARP1 [89]. 
A very different picture is displayed by spermatocytic 
tumour which originates from clonally-expanding ma-
ture spermatogonia, where hypo- and hyper-methy-
lated cells can be seen admixed next to each other, in 
a seemingly chaotic pattern [90].
In addition to DNA methylation, modifications of 
histones in nuclear chromatin are another mechanism 
of gene expression regulation. Histone modifications 
are variable in TGCT and can also be detected by im-
munohistochemistry. GCNIS cells are characterised 
by the virtual absence of restrictive histone modifica-
tions H3K9me2/3 and H3K27me3, and the abundance 
of H3K4me1, H3K4me2/3, H3K9ac and the histone 
variant H2A.Z, which are all modifications associated 
with active and permissive chromatin structure [84, 
91]. Moreover, GCNIS cells show high levels of H4/ 
/H2AR3me2 and simultaneously express BLIMP1/ 
/PRMT5, which is essential for PGC specification 
[92]. We hypothesise that the DNA hypo-methyl-
ation, the absence of DNA damage response and 
a high proliferation rate combined with ‘permissive’ 
chromatin modifications may render GCNIS vulner-
able to genomic instability and increased plasticity in 
response to exogenous factors [93].
Traces of GCT in blood: classical  
biochemical markers and micro-RNAs
Diagnosis of GCT in the clinic involves an obligatory 
step of taking a blood sample to measure by immuno-
assays a set of biochemical tumour markers; b-hCG, 
AFP and (in some centres) lactate dehydrogenase 
(LDH, LD-1) [94, 95]. These markers are helpful in 
the diagnosis and monitoring of GCT and are included 
in commonly used staging manuals. AFP and b-hCG 
are secreted by nonseminomatous tumours, yolk sac 
tumour and syncytiotrophoblast of choriocarcinoma 
(as mentioned above in the section on immunohisto-
chemical markers), whereas LDH is also secreted by 
seminoma. The presence of just a few giant cells in 
a seminoma may be sufficient to detect b-hCG in serum. 
LDH levels in serum may be increased if the tumour 
has a prominent gain of chromosome 12p, where the 
LDHB gene is located [96]. The interpretation of 
serum levels of these markers in patients with semi-
noma, pure EC and teratoma is sometimes difficult, 
and many cases are marker-negative. 
However, it can be expected that a new blood tests 
will become soon available. A recently discovered 
mechanism of post-genomic gene expression regula-
tion involves small non-coding RNAs, predominantly 
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micro-RNA (miRNA or miR), which are among the 
smallest (~22 bases long) RNAs, thus much less prone 
to degradation. MiRNAs inhibit gene expression by 
direct base-pairing with transcripts, and one miRNA 
may have many targets. These small RNAs act inside 
the cells, but recently it has become clear that miRNAs 
are actively secreted in exosome vesicles that can 
affect post-transcriptional regulation in a remote re-
cipient cell. GCT display micro-RNA profiles similar 
to embryonic stem cells, and these embryonic miRNA 
types are already highly upregulated and detectable 
in pre-invasive GCNIS cells [97]. Interestingly, the 
characteristic miRNA profiles are similar in GCT 
that arise in children and adults, and are detectable 
in all histological subtypes and components, except 
teratoma [21, 98, 99]. This specific TGCT profile, 
which was detected by several groups independently 
from each other, includes a high level of miR-371-3 
cluster, miR-302 and miR-367. Tests targeting these 
specific miRNAs are currently under development. 
Preliminary studies have already proven great spe-
cificity (99–100%) and sensitivity of these tests for 
the detection of TGCT [100–102]. Other body fluids 
are also suitable for detection of miRNA released 
by disseminated tumours, e.g. pleural effusion fluid. 
Importantly for testicular neoplasms, seminal plasma 
apparently also has elevated levels of specific miRNAs 
compared with controls [103]. These results are very 
promising and it is likely that miRNA-based assays 
will be routinely used for diagnosis and follow-up of 
the patients in not so distant future.
Conclusions
In conclusion, research advances over the years have 
provided clinicians with a panel of molecular markers, 
which allow specific diagnosis of germ cell tumours 
in a clinical laboratory setting. Immunohistochemical 
and histochemical markers in tissues remain used 
and are still the gold standard for pathology diagno-
sis. However, the existing biochemical serum assays 
will soon be supported — and in the future perhaps 
replaced — by novel more sensitive and specific tests 
that detect circulating products of tumour cells and 
are likely to improve early detection and monitoring 
of patients. 
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